Ann: Results from Data Confirmation Study, page-151

I would keep in mind that most medium to long term holders bought into the cough test story before the covid test came along. From what we have been told that is starting to get some traction and over the next few quarters if we can get in to a position of cash flow positive whilst continuing to develop the covid test I would expect the share price to head towards all time high with or without Pfizer or a covid test. It is by no means an all or nothing with Pfizer . The idea of giving the company away for a pittance when it is just starting its commercialisation journey seems irrational to me. Tele-Health is here now and will only grow in the future ,RAP has arguably the best respiratory diagnosis tool available ,maybe shareholder need to focus more on that than a covid test and Pfizer. The scheme offer from Pfizer was about 95 pages long and I would expect there are numerous options available within it for them to stall, lock down share price and generally manipulate shareholder sentiment to their advantage .If you are a shareholder and not aware of what RAP tech is all about ,I would strongly recommend reading up on what RAP can do before making a decision on the scheme